Friday, 20 July 2018 20:21

Anticoagulation news items. Week commencing 16th July 2018

Revised SPC: Xarelto (rivaroxaban) tablets - all strengths

electronic Medicines compendium

DRESS syndrome (Drug reaction with eosinophilia and systemic symptoms) noted in post-marketing reports (frequency very rare). Interaction with fluconazole/ erythromycin/clarythromycin not clinically relevant in most patients but potentially significant in high-risk patients.


Eltrombopag (Revolade): reports of interference with bilirubin and creatinine test results

Medicines and Healthcare products Regulatory Agency

Eltrombopag can cause serum discolouration and interference with the test results of creatinine and bilirubin. If these laboratory results are inconsistent with clinical observations, request re-testing using another method to determine the validity of the result.


Fatal or Irreversible Bleeding and Ischemic Events With Rivaroxaban in Acute Coronary Syndrome

Journal of the American College of Cardiology

Review of ATLAS ACS 2-TIMI 51 trial found that addition of rivaroxaban 2.5mg bd to aspirin and clopidogrel/ticlodipine was associated with 105 (95% CI 6-204) fewer fatal or irreversible events (including ischaemic and haemorrhagic events), per 10,000 patient years vs dual therapy.



The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at: